Jefferies London: Affinity Asset Advisors' Patrick Nosker shares a public investor's perspective on biotech and comments on a few of his firm's top positions
He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes. Brought to you by
3 days ago
Jefferies London: Medicxi announced a €500 million Fund V ahead of this week's conference - Co-founder Giovanni Mariggi describes the firm's asset-centric approach to investing in biotech
He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment. Coverage brought to you by
3 days ago
Jefferies London: Jefferies Chairman of Global Healthcare Philip Ross discusses the environment for biotech and deals
He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics. Coverage brought to you by
4 days ago
Stephenson Harwood lawyers discuss the keys to success for deal and partnering negotiations at London Life Science Week and beyond
Alexandra Pygall, Naomi Leach, Kristian Shearsby, and James Gubbins discuss best practices to get the most out of your deals. Brought to you by
5 days ago
Jefferies London: Jefferies M&A Banker Chris Roop shares his take on the environment for deals in biotech
He expects deals to continue in 2026, and says that the bidding wars we have seen recently are likely deal specific. Coverage brought to you by
6 days ago
Stifel's Head of Global Equity Capital Markets Seth Rubin describes the investor feedback he is hearing about the sector lately, and the fundraising environment for companies
He says that investors are placing fewer, but larger bets on companies lately, and he expects a 'healthy' IPO market in 2026. Coverage brought to you by
Nov 12
.png){kind=logo}
